VasoDynamics is a pharmaceutical development company

based in London, UK. We are a young company with young-at-heart executives

and a shared vision to improve the standard of cancer care globally.

​

Recognising the mounting cost pressures facing healthcare payers all over the world, we are developing a number of cost-efficient medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy.

​

We take great pride in our culture of scientific and development rigour, and our programmes are based on robust science from world-leading research bodies.

 

 

​

Our focus 

is to develop patient-friendly and preventative and therapies that make a major and positive difference to cancer patients’ well-being and quality of life, with substantial payer savings potential. 

​

Our pipeline 

comprises 3 differentiated radio-protection programmes for topical administration. 

​

Our Intellectual Property

is protected by global patents and based on groundbreaking research at University of Wisconsin-Madison in the field of radioprotection.

​

Our team 

includes executives with decades of individual experience across Medicine, Radiotherapy, Regulatory Affairs, Drug Development and Commercialisation.

 

​

Our lead programme

 NG11 for the prevention of radiotherapy-induced oral mucositis(RIOM) is due to enter clinical trials in 2020